Santersus Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Reverse Merger
  • (Announced)

  • Investors
  • 2

Santersus General Information

Description

Developer of a therapeutic apheresis technology designed to control human immune and inflammatory responses to disease. The company's technology focuses on the extracorporeal removal of cell-free DNA and neutrophil extracellular traps from patient plasma, enabling healthcare providers to treat severe inflammatory conditions and improve patient outcomes in critical care.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Care of Lex Futura AG Nüschelerstrasse 45
  • 8001 Zürich
  • Switzerland
+41 044
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Biotechnology
Drug Discovery
Corporate Office
  • Care of Lex Futura AG Nüschelerstrasse 45
  • 8001 Zürich
  • Switzerland
+41 044

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Santersus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Reverse Merger 16-Sep-2026 Announced Clinical Trials - General
4. Later Stage VC (Series A) 25-Apr-2025 Completed Clinical Trials - General
3. Early Stage VC 01-Jul-2021 Completed Clinical Trials - General
2. Seed Round 01-Sep-2020 $1.11M $1.93M Completed Clinical Trials - General
1. Capitalization 01-Sep-2020 $824K $824K Completed Clinical Trials - General
To view Santersus’s complete valuation and funding history, request access »

Santersus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 192,306 $0.117130 $4.57 $4.57 1x $4.57 8.88%
Ordinary 62,768 $0.117130 $4.83 $4.83 1x $4.83 2.9%
To view Santersus’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Santersus Patents

Santersus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025048683-A1 Method for detection and quantification of cell free dna in biological sample Inactive 25-Aug-2023
US-12053567-B2 Method and device for removal of circulating cell free dna Active 27-Dec-2021
US-20230201439-A1 Method and device for removal of circulating cell free dna Active 27-Dec-2021
WO-2023126672-A1 Method and device for removal of circulating cell free dna Inactive 27-Dec-2021
WO-2022214873-A1 The method and device for purification of blood from circulating citrullinated histones and neutrophil extracellular traps (nets) Inactive 05-Apr-2021 A61M1/3679
To view Santersus’s complete patent history, request access »

Santersus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Santersus Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Norcliffe Capital Venture Capital Minority
Terumo Ventures Corporate Venture Capital Minority
To view Santersus’s complete investors history, request access »

Santersus Acquisitions (1)

Santersus’s most recent deal was a Merger/Acquisition with Xenetic Biosciences. The deal was made on 16-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xenetic Biosciences 16-Sep-2026 Merger/Acquisition Drug Discovery
To view Santersus’s complete acquisitions history, request access »

Santersus FAQs

  • When was Santersus founded?

    Santersus was founded in 2017.

  • Where is Santersus headquartered?

    Santersus is headquartered in Zürich, Switzerland.

  • What is the size of Santersus?

    Santersus has 7 total employees.

  • What industry is Santersus in?

    Santersus’s primary industry is Therapeutic Devices.

  • Is Santersus a private or public company?

    Santersus is a Private company.

  • What is Santersus’s current revenue?

    The current revenue for Santersus is .

  • How much funding has Santersus raised over time?

    Santersus has raised $8.35M.

  • Who are Santersus’s investors?

    Norcliffe Capital and Terumo Ventures have invested in Santersus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process